Table 2 Baseline characteristics of subjects with non-ST elevation myocardial infarction after propensity score matching.
Clopidogrel | Ticagrelor | p-value | |
|---|---|---|---|
(N = 1303) | (N = 1303) | ||
Age (mean ± SD) | 63.00 ± 14.23 | 62.99 ± 13.42 | 0.991 |
Age < 65 | 738 (56.6%) | 736 (56.5%) | 0.937 |
Age > = 65 | 565 (43.4%) | 567 (43.5%) | |
Male | 1030 (79.0%) | 1020 (78.3%) | 0.633 |
Risk factors | |||
Dyslipidemia | 464 (35.6%) | 464 (35.6%) | 1.000 |
Hypertension | 685 (52.6%) | 703 (54.0%) | 0.480 |
Diabetes mellitus | 566 (43.4%) | 561 (43.1%) | 0.843 |
Cardiovascular history | |||
Coronary artery disease | 496 (38.1%) | 494 (37.9%) | 0.936 |
Prior myocardial infarction | 201 (15.4%) | 193 (14.8%) | 0.662 |
Heart failure | 155 (11.9%) | 150 (11.5%) | 0.761 |
Atrial fibrillation | 32 (2.5%) | 26 (2.0%) | 0.426 |
Peripheral vascular disease | 17 (1.3%) | 20 (1.5%) | 0.619 |
Comorbidity | |||
Renal dysfunction | 140 (10.7%) | 145 (11.1%) | 0.754 |
Peptic ulcers | 185 (14.2%) | 179 (13.7%) | 0.735 |
Ischemic stroke | 131 (10.1%) | 121 (9.3%) | 0.508 |
Intracerebral hemorrhage | 7 (0.5%) | 9 (0.7%) | 0.616 |
Cancer | 168 (12.9%) | 153 (11.7%) | 0.371 |
Chronic obstructive pulmonary disease | 168 (12.9%) | 176 (13.5%) | 0.643 |
In-hospital procedure or surgery | |||
Intra-aortic balloon pump | 47 (3.6%) | 44 (3.4%) | 0.749 |
Revascularization | 1112 (85.3%) | 1102 (84.6%) | 0.584 |
Percutaneous coronary intervention | 1109 (85.1%) | 1099 (84.3%) | 0.586 |
Coronary artery bypass graft | 5 (0.4%) | 3 (0.2%) | 0.479 |
In-hospital drug use | |||
Beta blocker | 959 (73.6%) | 959 (73.6%) | 1.000 |
ACEI or ARB | 1011 (77.6%) | 1008 (77.4%) | 0.888 |
Statin | 1070 (82.1%) | 1080 (82.9%) | 0.606 |
Calcium channel blocker | 398 (30.5%) | 414 (31.8%) | 0.499 |
PPI | 172 (13.2%) | 170 (13.0%) | 0.908 |
GP IIb/IIa inhibitor | 56 (4.3%) | 57 (4.4%) | 0.923 |
